143 related articles for article (PubMed ID: 35185017)
1. A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary.
Chelariu-Raicu A; Holley E; Mayr D; Klauschen F; Wehweck F; Rottmann M; Kessler M; Kaltofen T; Czogalla B; Trillsch F; Mahner S; Schmoeckel E
Int J Gynecol Cancer; 2022 May; 32(5):662-668. PubMed ID: 35185017
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
[TBL] [Abstract][Full Text] [Related]
3. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
Meagher NS; Wang L; Rambau PF; Intermaggio MP; Huntsman DG; Wilkens LR; El-Bahrawy MA; Ness RB; Odunsi K; Steed H; Herpel E; Anglesio MS; Zhang B; Lambie N; Swerdlow AJ; Lubiński J; Vierkant RA; Goode EL; Menon U; Toloczko-Grabarek A; Oszurek O; Bilic S; Talhouk A; García-Closas M; Wang Q; Tan A; Farrell R; Kennedy CJ; Jimenez-Linan M; Sundfeldt K; Etter JL; Menkiszak J; Goodman MT; Klonowski P; Leung Y; Winham SJ; Moysich KB; Behrens S; Kluz T; Edwards RP; Gronwald J; Modugno F; Hernandez BY; Chow C; Kelemen LE; Keeney GL; Carney ME; Natanzon Y; Robertson G; Sharma R; Gayther SA; Alsop J; Luk H; Karpinskyj C; Campbell I; Sinn P; Gentry-Maharaj A; Coulson P; Chang-Claude J; Shah M; Widschwendter M; Tang K; Schoemaker MJ; Koziak JM; Cook LS; Brenton JD; Daley F; Kristjansdottir B; Mateoiu C; Larson MC; Harnett PR; Jung A; deFazio A; Gorringe KL; Pharoah PDP; Minoo P; Stewart C; Bathe OF; Gui X; Cohen P; Ramus SJ; Köbel M
Mod Pathol; 2019 Dec; 32(12):1834-1846. PubMed ID: 31239549
[TBL] [Abstract][Full Text] [Related]
4. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm.
Aldaoud N; Erashdi M; AlKhatib S; Abdo N; Al-Mohtaseb A; Graboski-Bauer A
BMC Res Notes; 2019 Nov; 12(1):770. PubMed ID: 31771640
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas.
Ji H; Isacson C; Seidman JD; Kurman RJ; Ronnett BM
Int J Gynecol Pathol; 2002 Oct; 21(4):391-400. PubMed ID: 12352188
[TBL] [Abstract][Full Text] [Related]
6. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
Ates Ozdemir D; Usubutun A
Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
Strickland S; Parra-Herran C
Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma.
Albarracin CT; Jafri J; Montag AG; Hart J; Kuan SF
Hum Pathol; 2000 Jun; 31(6):672-7. PubMed ID: 10872659
[TBL] [Abstract][Full Text] [Related]
9. Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.
Wang F; Yang Y; Du X; Zhu X; Hu Y; Lu C; Sui L; Zhao H; Song K; Yao Q
BMC Cancer; 2023 Jan; 23(1):44. PubMed ID: 36639622
[TBL] [Abstract][Full Text] [Related]
10. SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): A series of seven cases.
Schmoeckel E; Kirchner T; Mayr D
Pathol Res Pract; 2018 Mar; 214(3):426-430. PubMed ID: 29487003
[TBL] [Abstract][Full Text] [Related]
11. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.
Wang M; Ma H; Pan Y; Xiao W; Li J; Yu J; He J
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):280-7. PubMed ID: 24992169
[TBL] [Abstract][Full Text] [Related]
12. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of MUC1, MUC2 and MUC5AC expressions in gastric carcinoma.
İlhan Ö; Han Ü; Önal B; Çelık SY
Turk J Gastroenterol; 2010 Dec; 21(4):345-52. PubMed ID: 21331986
[TBL] [Abstract][Full Text] [Related]
14. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
Vang R; Gown AM; Zhao C; Barry TS; Isacson C; Richardson MS; Ronnett BM
Am J Surg Pathol; 2007 Jun; 31(6):854-69. PubMed ID: 17527072
[TBL] [Abstract][Full Text] [Related]
15. MUC5AC expression is linked to mucinous/endometroid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer.
Rico SD; Schmalfeldt B; Müller V; Wölber L; Witzel I; Paluchowski P; von Leffern I; Heilenkötter U; Jacobsen F; Bernreuther C; Clauditz T; Simon R; Steurer S; Burandt E; Marx AH; Krech T
Pathol Res Pract; 2021 Aug; 224():153533. PubMed ID: 34171599
[TBL] [Abstract][Full Text] [Related]
16. [Mucinous ovarian neoplasms. Prognostically mostly excellent, infrequently a wolf in sheep's clothing].
Lax S; Staebler A
Pathologe; 2014 Jul; 35(4):327-35. PubMed ID: 24962632
[TBL] [Abstract][Full Text] [Related]
17. Expression profile of mucins in ovarian mucinous tumors: distinguishing primary ovarian from metastatic tumors.
Wang J; El-Bahrawy MA
Int J Gynecol Pathol; 2014 Mar; 33(2):166-75. PubMed ID: 24487472
[TBL] [Abstract][Full Text] [Related]
18. Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality.
Hu A; Li H; Zhang L; Ren C; Wang Y; Liu Y; Liu C
J Clin Pathol; 2015 Jul; 68(7):522-8. PubMed ID: 25827135
[TBL] [Abstract][Full Text] [Related]
19. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.
Elias KM; Labidi-Galy SI; Vitonis AF; Hornick JL; Doyle LA; Hirsch MS; Cramer DW; Drapkin R
Gynecol Oncol; 2014 Feb; 132(2):328-33. PubMed ID: 24342438
[TBL] [Abstract][Full Text] [Related]
20. Expression of REG4 in ovarian mucinous tumors.
Huang Q; Chen X; Lu W; Lai M; Lu B
Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):295-301. PubMed ID: 23958547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
